OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
Michael E. Lidsky, Zechen Wang, Min Lu, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 12
Michael E. Lidsky, Zechen Wang, Min Lu, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 12
Showing 12 citing articles:
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Diego F. Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 462-480
Open Access | Times Cited: 23
Diego F. Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 462-480
Open Access | Times Cited: 23
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2181-2192
Closed Access | Times Cited: 4
Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2181-2192
Closed Access | Times Cited: 4
The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma
Y. Ito, Daisaku Yamada, Shogo Kobayashi, et al.
Cancer Letters (2024) Vol. 595, pp. 216997-216997
Closed Access | Times Cited: 4
Y. Ito, Daisaku Yamada, Shogo Kobayashi, et al.
Cancer Letters (2024) Vol. 595, pp. 216997-216997
Closed Access | Times Cited: 4
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
Zechen Wang, Viswanathan Muthusamy, Daniel P. Petrylak, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 7
Zechen Wang, Viswanathan Muthusamy, Daniel P. Petrylak, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 7
The roles of epigenetic regulation in cholangiocarcinogenesis
Baiyin Zhong, Qicheng Liao, Xin Wei Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115290-115290
Open Access | Times Cited: 6
Baiyin Zhong, Qicheng Liao, Xin Wei Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115290-115290
Open Access | Times Cited: 6
An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy
Sihui Zhu, Chenxi Liu, Yunchen Jin, et al.
Inflammation (2024) Vol. 47, Iss. 5, pp. 1699-1705
Open Access | Times Cited: 2
Sihui Zhu, Chenxi Liu, Yunchen Jin, et al.
Inflammation (2024) Vol. 47, Iss. 5, pp. 1699-1705
Open Access | Times Cited: 2
Identification of cancer-related genes FGFR2 and CEBPB in choledochal cyst via RNA sequencing of patient-derived liver organoids
Yongqin Ye, Vincent Chi Hang Lui, Rosana Ottakandathil Babu, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0283737-e0283737
Open Access | Times Cited: 4
Yongqin Ye, Vincent Chi Hang Lui, Rosana Ottakandathil Babu, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0283737-e0283737
Open Access | Times Cited: 4
Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
Michał Wasilewicz, Rafał Becht
Medicina (2023) Vol. 59, Iss. 4, pp. 729-729
Open Access | Times Cited: 3
Michał Wasilewicz, Rafał Becht
Medicina (2023) Vol. 59, Iss. 4, pp. 729-729
Open Access | Times Cited: 3
Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib
Ludovica Gnagni, Ilary Ruscito, Ilaria Grazia Zizzari, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 202, pp. 104464-104464
Open Access
Ludovica Gnagni, Ilary Ruscito, Ilaria Grazia Zizzari, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 202, pp. 104464-104464
Open Access
Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy
Xing Ma, Yangyang Zhou, Ruping Li, et al.
Molecular Carcinogenesis (2024) Vol. 63, Iss. 10, pp. 1866-1873
Closed Access
Xing Ma, Yangyang Zhou, Ruping Li, et al.
Molecular Carcinogenesis (2024) Vol. 63, Iss. 10, pp. 1866-1873
Closed Access
Patient-derived tumor models in cancer research: Evaluation of the oncostatic effects of melatonin
Laura Martinez‐Ruiz, Alba López‐Rodríguez, Javier Florido, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115581-115581
Open Access | Times Cited: 1
Laura Martinez‐Ruiz, Alba López‐Rodríguez, Javier Florido, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115581-115581
Open Access | Times Cited: 1
An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalised Immunotherapy and FGFR2 Inhibiter
Sihui Zhu, Chenxi Liu, Yunchen Jin, et al.
Research Square (Research Square) (2023)
Open Access
Sihui Zhu, Chenxi Liu, Yunchen Jin, et al.
Research Square (Research Square) (2023)
Open Access
